Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna is laying off 10% of its workforce. Does RFK Jr. have anything to do with it?
08:40am, Friday, 01'st Aug 2025
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
Moderna Stock Drops After Earnings Report. What Has Wall Street Worried.
07:23am, Friday, 01'st Aug 2025
Moderna stock was falling in Friday's premarket after the drugmaker's better-than-expected quarterly results were overshadowed by a cut to the high end of its full-year outlook.
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
07:08am, Friday, 01'st Aug 2025
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts.
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
07:03am, Friday, 01'st Aug 2025
Moderna lowered the high end of its 2025 revenue outlook, citing a delay in vaccine shipments to the U.K. The company lost less than Wall Street analysts were expecting for the second quarter and po
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
07:00am, Friday, 01'st Aug 2025
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reducti
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
06:00am, Friday, 01'st Aug 2025
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
05:59am, Friday, 01'st Aug 2025
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
04:37am, Friday, 01'st Aug 2025
Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1.
More than 800 Moderna employees will lose their jobs this year as costs are slashed
09:14am, Thursday, 31'st Jul 2025
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the biotechnology company's plan to cut costs by $1.5 billion over the next couple
Moderna plans to lay off 10% of workforce to cut costs
07:34am, Thursday, 31'st Jul 2025
Moderna plans to trim roughly 10% of its global workforce by the end of the year to cut costs amid declining sales of its COVID-19 vaccines, the company said on Thursday.
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
07:15am, Thursday, 31'st Jul 2025
Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In
Pandemic darlings Moderna, BioNTech are now on two different paths
07:00am, Thursday, 31'st Jul 2025
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
04:05pm, Wednesday, 30'th Jul 2025
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the C
